Table 3 Association of ISUP grade (n = 189), PSA level (n = 194) and ADT (n = 14) with the presence/absence of metastatic disease
From: Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging
|  | No metastasis | Metastasis present | Univariable modela | Multivariable modela (n = 189) | ||
|---|---|---|---|---|---|---|
Unadjusted ORÂ (95%CI) | p-value | Adjusted ORÂ (95%CI) | p-value | |||
n = 128 | n = 66 | |||||
Age (years), mean (SD) | 68.9 (7.5) | 69.9 (8.6) | 1.02 (0.98,1.06) | 0.39 | Â | Â |
ISUP Grade | Â | Â | Â | 0.014 | Â | 0.008 |
ISUP 1 | 88% (7/8) | 13% (1/8) | 0.42 (0.05,3.62) | Â | 0.32 (0.03,3.00) | Â |
ISUP 2 and 3 | 75% (68/91) | 25% (23/91) | (reference) | Â | (reference) | Â |
ISUP 4 and 5 | 57% (51/90) | 43% (39/90) | 2.26 (1.20,4.25)* | Â | 2.64 (1.34,5.23)** | Â |
PSA levels (ng/mL) | Â | Â | Â | 0.004 | Â | 0.001 |
\(\le\) 10 | 71.3% (72/101) | 28.7% (29/101) | (reference) | Â | (reference) | Â |
10–20 | 74.0% (37/50) | 26.0% (13/50) | 0.87 (0.41,1.87) |  | 0.93 (0.42,2.07) |  |
 > 20 | 44.2% (19/43) | 55.8% (24/43) | 3.14 (1.50,6.58)** |  | 4.33 (1.89,9.91)*** |  |
Previous or current ADT use | Â | Â | Â | 0.198 | Â | 0.198 |
No | 67.2% (121/180) | 32.8% (59/180) | (reference) | Â | (reference) | Â |
Yes | 50.0% (7/14) | 50.0% (7/14) | 2.05 (0.69,6.12) | Â | 2.16 (0.67,6.96) | Â |